A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients with Newly Di-agnosed MGMT-promoter Unmethylated Glioblastoma
MD Anderson Study Status
This phase I trial studies the side effects and best dose of tinostamustine (EDO-S101) given with or without radiation therapy in treating patients with newly diagnosed MGMT-unmethylated glioblastoma. Tinostamustine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in patients with glioblastoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.